Ashurst and Linklaters have taken the lead roles on a developmen t agreement between drug giant AstraZeneca and UK pharmaceutical company Protheric s worth £195m.
The agreement, for a Protherics drug to treat blood poisoning called CytoFab, includes an initial payment of £16m to Protherics and a £7.5m equity investment by AstraZeneca. Protherics will also receive additional payments for reaching development targets and, if the product is launched, it will receive royalties on global sales.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
